New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
The sprouting of new blood vessels, or angiogenesis, is necessary for any solid tumor to grow large enough to cause life-threatening disease. Vascular endothelial growth factor (VEGF) is one of the key promoters of tumor induced angiogenesis. VEGF receptors, the tyrosine kinases Flt-1 and KDR, are expressed on vascular endothelial cells and initiate angiogenesis upon activation by VEGF. 1-Anilino-(4-pyridylmethyl)-phthalazines, such as CGP 79787D (or PTK787 / ZK222584), reversibly inhibit Flt-1 and KDR with IC(50) values < 0.1 microM. CGP 79787D also blocks the VEGF-induced receptor autophosphorylation in CHO cells ectopically expressing the KDR receptor (ED(50) = 34 nM). Modification of the 1-anilino moiety afforded derivatives with higher selectivity for the VEGF receptor tyrosine kinases Flt-1 and KDR compared to the related receptor tyrosine kinases PDGF-R and c-Kit. Since these 1-anilino-(4-pyridylmethyl)phthalazines are orally well absorbed, these compounds qualify for further profiling and as candidates for clinical evaluation.
Bold
G
G
Oncology Research, and Process Research, NOVARTIS Pharma AG, CH-4002 Basel, Switzerland. guido.bold@pharma.novartis.com
Altmann
K H
KH
Frei
J
J
Lang
M
M
Manley
P W
PW
Traxler
P
P
Wietfeld
B
B
Brüggen
J
J
Buchdunger
E
E
Cozens
R
R
Ferrari
S
S
Furet
P
P
Hofmann
F
F
Martiny-Baron
G
G
Mestan
J
J
Rösel
J
J
Sills
M
M
Stover
D
D
Acemoglu
F
F
Boss
E
E
Emmenegger
R
R
Lässer
L
L
Masso
E
E
Roth
R
R
Schlachter
C
C
Vetterli
W
W
D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001682:Biological Availability; D016466:CHO Cells; D002460:Cell Line; D006224:Cricetinae; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D009369:Neoplasms / Q000098:blood supply; D009389:Neovascularization, Pathologic; D010766:Phosphorylation; D010793:Phthalazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors; D011725:Pyridines; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors* / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor; D013329:Structure-Activity Relationship; D014162:Transfection; D040281:Vascular Endothelial Growth Factor Receptor-1
D020533:Angiogenesis Inhibitors; D000814:Aniline Compounds; D004791:Enzyme Inhibitors; D010793:Phthalazines; D011518:Proto-Oncogene Proteins; D011725:Pyridines; D017978:Receptors, Growth Factor; C404768:vatalanib; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1